Penile Injection Therapy (ICI / Trimix)
Intracavernosal alprostadil, Trimix, Bimix
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Approved (alprostadil 1995); Trimix is compounded, not FDA-approved
Reference only. Not medical advice.
What can go wrong
Priapism, a prolonged erection beyond 4 hours, is a medical emergency requiring prompt treatment to avoid permanent fibrosis. Repeated injections can cause penile fibrosis and curvature; alprostadil commonly causes penile pain or aching. Bleeding, bruising, and dosing errors are risks of self-injection. Proper titration under urologic supervision is essential.
This is something to take to a clinician. The Atlas can tell you what is known about penile injection therapy (ici / trimix) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Intracavernosal injection (ICI) delivers a vasoactive agent directly into the corpus cavernosum to induce an erection independent of nitric oxide signaling. Single-agent alprostadil (Caverject, Edex) is FDA-approved; compounded Trimix (papaverine + phentolamine + alprostadil) and Bimix combinations are widely used through urology practices. Reported response rates are high (often cited around 70-90% in case series), including in many men who failed PDE5 inhibitors.
Second-line therapy that works even when the pills fail.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Alprostadil (prostaglandin E1) directly relaxes cavernosal smooth muscle and dilates arteries; papaverine is a non-specific phosphodiesterase inhibitor and smooth-muscle relaxant; phentolamine is an alpha-adrenergic blocker that reduces vasoconstrictive tone. Because the effect is local and arousal-independent, ICI works where oral agents fail.
What people get wrong
Often saidInjections are dangerous and barbaric
ActuallyWith training and correct dosing, ICI is a well-tolerated, highly effective second-line therapy. The fine 27-30G needle into the side of the shaft is far less painful than men anticipate.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Gilles Brindley demonstrated intracavernosal papaverine in 1983 by injecting himself on stage at a urology conference and dropping his trousers to show the result. Alprostadil received FDA approval in 1995.
At a glance
- Demonstrated
- 1982-83 (Virag papaverine; Brindley alpha-blockade)
- Alprostadil approval
- 1995
- Reported response
- ~70-90% (case series)
- Trimix status
- Compounded, not FDA-approved
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Penile Injection Therapy (ICI / Trimix). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.